insights_auto
Miks on ALNOV langenud? 3,41%?
Uurige põhjalikumaltchevron_right
ALNOV:EPA
Novacyt SA
0,42 €
arrow_downward
−3,41%(−0,015) 1 p
20. nov, 11:03:40 GMT +1 · EUR
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse ALNOV põhistatistika genereerimine…
Ava
0,43 €
Kõrge
0,44 €
Madal
0,42 €
Turu kapit.
30,77 mln
Keskm. maht
128,00 tuh
Maht
32,94 tuh
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
72,59 mln
Töötajate arv
228
Ava
0,43 €
Kõrge
0,44 €
Madal
0,42 €
Turu kapit.
30,77 mln
Keskm. maht
128,00 tuh
Maht
32,94 tuh
52 näd kõrgeim
1,04 €
52 näd madalaim
0,29 €
Aktsiatulu
−0,38 €
Käibivad aktsiad
72,59 mln
Töötajate arv
228
Uudised
Veebiallikatest ja uudistepartneritelt
MarketWatch
·
11 minuti eest
Here’s what happened next after previous times the S&P 500 losing streak reached six sessions
Benzinga
·
9 minuti eest
Stock Market Today: Dow Jones, S&P 500 Futures Fall as Trump Weighs Iran Decision— INTU, ROST, KEYS in Fo
Adam Feldman | Substack
·
16 tunni eest
Inside the Federal Litigation of Five S&P 500 Giants
Profiil
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Teave üksuse Novacyt SA kohta
TegevjuhtDavid Allmond
Töötajad228
Asutatud3. juuli 2006
Peakontorid-
SektorHealth Care
Valdkond-
Veebisaitnovacyt.com